Ambrilia Biopharma Inc. Sells Prostate Cancer Drug Candidate to Kotinos Pharmaceuticals Inc. for up to $15 Million
Reuters -- Small Canadian biotech company Ambrilia Biopharma Inc said it agreed to sell its experimental prostate cancer drug, PCK3145, to Kotinos Pharmaceuticals Inc.